SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007; 37: 676-691.
  • 2
    Marelli L, Stigliano R, Triantos C, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006; 32: 594-606.
  • 3
    Ren ZG, Lin ZY, Xia JL, et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol. 2004; 10: 2791-2794.
  • 4
    Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009; 198: 313-318.
  • 5
    Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17: 409-402.
  • 6
    Okada S, Okazaki N, Nose H, et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology. 1993; 50: 22-26.
  • 7
    Ikeda M, Maeda S, Shibata J, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology. 2004; 66: 24-31.
  • 8
    Ikeda M, Maeda S, Ashihara H, et al. Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol. 2010; 45: 60-67.
  • 9
    Ishikawa T. Future perspectives of the treatment of hepatocellular carcinoma with cisplatin. World J Hepatol. 2009; 1: 8-16.
  • 10
    Yamashita F, Tanaka M, Andou E, et al. Carboplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Oncology. 1997; 54: 28-33.
  • 11
    Kagawa T, Koizumi J, Kojima S, et al. Tokai RFA Study Group. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010; 116: 3638-3644.
  • 12
    Sakon M, Umeshita K, Nagano H, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg. 2000; 135: 1456-1459.
  • 13
    Imaoka S, Sasaki Y. Pre- and/or postoperative adjuvant therapy for hepatocellular carcinoma [in Japanese]. Nippon Geka Gakkai Zasshi. 1998; 99: 229-233.
  • 14
    Zhang Z, Liu Q, He J, Yang J, Yang G, Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer. 2000; 89: 2606-2612.
  • 15
    Di Carlo V, Ferrari G, Castoldi R, et al. Pre-operative chemoembolization of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology. 1998; 45: 1950-1954.
  • 16
    Paye F, Jagot P, Vilgrain V, Farges O, Borie D, Belghiti J. Preoperative chemoembolization of hepatocellular carcinoma: a comparative study. Arch Surg. 1998; 133: 767-772.
  • 17
    Nagasue N, Kohno H, Uchida M. Evaluation of preoperative transcatheter arterial embolization in the treatment of resectable primary liver cancer. Semin Surg Oncol. 1993; 9: 327-331.
  • 18
    Uchida M, Kohno H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg. 1996; 20: 326-331.
  • 19
    Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg. 1995; 82: 122-126.
  • 20
    Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res. 1996; 87: 206-211.
  • 21
    Ishikawa T, Ichida T, Ishimoto Y, et al. Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. Am J Gastroenterol. 1999; 94: 1682-1685.
    Direct Link:
  • 22
    Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol. 2001; 16: 452-459.
  • 23
    Ishikawa T, Ichida T, Yokoyama J, Matsuda Y, Watanabe T, Asakura H. Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy. J Gastroenterol Hepatol. 2004; 19: 1423-1426.
  • 24
    Tsuchiya A, Imai M, Kamimura H, et al. Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil. World J Gastroenterol. 2009; 15: 1779-1781.
  • 25
    Court WS, Order SE, Siegel JA, et al. Remission and survival following monthly intra-arterial cisplatinum in nonresectable hepatoma. Cancer Invest. 2002; 20: 613-625.
  • 26
    Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008; 38: 474-483.
  • 27
    Colleoni M, Vicario G, Manente P, De Braud F, Fazio N, Liessi G. Activity and tolerability of courses of intra-arterial chemotherapy followed by chemoembolization in unresectable hepatocellular carcinoma. Tumori. 1998; 84: 673-676.
  • 28
    Homma H, Mezawa S, Doi T, et al. A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV). Hepatogastroenterology. 2004; 51: 1135-1139.
  • 29
    Yin XY, Shen Q, Lu MD, Xie XY. Ultrasound-guided percutaneous boiling carboplatin injection (PBCI) for the treatment of small hepatocellular carcinoma: a preliminary study. Hepatogastroenterology. 2004; 51: 1129-1134.
  • 30
    Lu W, Li YH, He XF, Zhao JB, Chen Y, Mei QL. Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. Cardiovasc Intervent Radiol. 2008; 31: 1133-1140.
  • 31
    Woo HY, Jang JW, Choi JY, et al. Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2010; 45: 332-339.